FI63494C - Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod - Google Patents
Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod Download PDFInfo
- Publication number
- FI63494C FI63494C FI763446A FI763446A FI63494C FI 63494 C FI63494 C FI 63494C FI 763446 A FI763446 A FI 763446A FI 763446 A FI763446 A FI 763446A FI 63494 C FI63494 C FI 63494C
- Authority
- FI
- Finland
- Prior art keywords
- factor
- activity
- sulphate
- polysaccharide
- xal
- Prior art date
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title claims description 6
- 238000005057 refrigeration Methods 0.000 title 1
- 230000000694 effects Effects 0.000 claims description 29
- 108010074860 Factor Xa Proteins 0.000 claims description 24
- 229920001282 polysaccharide Polymers 0.000 claims description 22
- 239000005017 polysaccharide Substances 0.000 claims description 22
- 150000004676 glycans Chemical class 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 15
- 238000011534 incubation Methods 0.000 claims description 13
- 229960000633 dextran sulfate Drugs 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 8
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 claims description 7
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 7
- 229920002971 Heparan sulfate Polymers 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229940051593 dermatan sulfate Drugs 0.000 claims description 4
- 229960002086 dextran Drugs 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- 108090000371 Esterases Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 230000003024 amidolytic effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims 3
- 239000003086 colorant Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 15
- 229920000669 heparin Polymers 0.000 description 15
- 229960002897 heparin Drugs 0.000 description 15
- 108090000190 Thrombin Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 150000002772 monosaccharides Chemical group 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 206010020608 Hypercoagulation Diseases 0.000 description 3
- 230000002429 anti-coagulating effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003027 hypercoagulation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940127234 oral contraceptive Drugs 0.000 description 3
- 239000003539 oral contraceptive agent Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 108010014173 Factor X Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XUMBUIZXGGMMIM-ODZAUARKSA-N 2-aminoethanol;(z)-but-2-enedioic acid Chemical compound NCCO.OC(=O)\C=C/C(O)=O XUMBUIZXGGMMIM-ODZAUARKSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000968 Parkia biglobosa Species 0.000 description 1
- 235000015754 Parkia biglobosa Nutrition 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108010007568 Protamines Chemical class 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000282 fibrinogen degradation product Substances 0.000 description 1
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- -1 polysaccharide sulfates Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 230000003558 thrombophilic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96444—Factor X (3.4.21.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7513495A SE419871B (sv) | 1975-12-01 | 1975-12-01 | Sett att bestemma aktiviteten hos faktor xa-inhibitor i blod |
| SE7513495 | 1975-12-01 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI763446A FI763446A (de) | 1977-06-02 |
| FI63494B FI63494B (fi) | 1983-02-28 |
| FI63494C true FI63494C (fi) | 1983-06-10 |
Family
ID=20326201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI763446A FI63494C (fi) | 1975-12-01 | 1976-11-30 | Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4139415A (de) |
| JP (1) | JPS5915640B2 (de) |
| AT (1) | AT348687B (de) |
| AU (1) | AU508343B2 (de) |
| BE (1) | BE848932A (de) |
| CA (1) | CA1060324A (de) |
| CH (1) | CH625052A5 (de) |
| DE (1) | DE2654189C3 (de) |
| DK (1) | DK537676A (de) |
| FI (1) | FI63494C (de) |
| FR (1) | FR2334109A1 (de) |
| GB (1) | GB1562808A (de) |
| NL (1) | NL7613376A (de) |
| NO (1) | NO148960C (de) |
| SE (1) | SE419871B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2757992A1 (de) | 1977-12-24 | 1979-06-28 | Boehringer Mannheim Gmbh | Verfahren zur prothrombin-bestimmung |
| US4302538A (en) * | 1978-03-27 | 1981-11-24 | Ortho Diagnostics Inc. | Buffer system in an anti-thrombin III test |
| SE422081B (sv) * | 1979-08-22 | 1982-02-15 | Ird Biomaterial Ab | Sett att pavisa proteolytiska enzymer |
| CA1161432A (en) * | 1980-02-12 | 1984-01-31 | Lars G. Svendsen | Tripeptide derivatives and their application in assaying enzymes |
| WO1982001377A1 (en) * | 1980-10-09 | 1982-04-29 | Lill Helmut | Method for determining a bm-antithrombin |
| US4753875A (en) * | 1981-11-02 | 1988-06-28 | Ryan James W | Method for assaying proteases with tagged proteinaceous inhibitors |
| US5221614A (en) * | 1988-03-03 | 1993-06-22 | Nippon Shoji Kabushiki Kaisha | Method and reagent for determining the biological activity of antithrombin III by measuring coagulation time |
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| DE19634312A1 (de) * | 1996-08-24 | 1998-02-26 | Behringwerke Ag | Verfahren zur Herstellung von Faktor V-Mangelplasma und ein so erhaltenes Mangelplasma |
| US6432658B1 (en) | 2000-09-13 | 2002-08-13 | Affinity Biologicals, Inc. | Method for measuring antithrombin activity |
| EP2818871A1 (de) * | 2013-06-28 | 2014-12-31 | Roche Diagniostics GmbH | Mittel und Verfahren zur universellen Kalibrierung von anti-Faktor-Xa-Tests |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE380257B (sv) * | 1972-05-02 | 1975-11-03 | Bofors Ab | Nya diagnostiskt verksamma substrat med hog specificitet till trombin och andra proteolytiska enzymer av typen peptidyl-peptid-hydrolaser |
| US3985618A (en) * | 1975-05-02 | 1976-10-12 | Irving Innerfield | Method for detection of thrombosis and prethrombosis |
-
1975
- 1975-12-01 SE SE7513495A patent/SE419871B/xx unknown
-
1976
- 1976-11-23 US US05/744,227 patent/US4139415A/en not_active Expired - Lifetime
- 1976-11-29 GB GB49679/76A patent/GB1562808A/en not_active Expired
- 1976-11-29 AU AU20061/76A patent/AU508343B2/en not_active Expired
- 1976-11-30 BE BE172864A patent/BE848932A/xx not_active IP Right Cessation
- 1976-11-30 DK DK537676A patent/DK537676A/da unknown
- 1976-11-30 NO NO764081A patent/NO148960C/no unknown
- 1976-11-30 DE DE2654189A patent/DE2654189C3/de not_active Expired
- 1976-11-30 FI FI763446A patent/FI63494C/fi not_active IP Right Cessation
- 1976-11-30 CA CA266,874A patent/CA1060324A/en not_active Expired
- 1976-12-01 CH CH1514576A patent/CH625052A5/de not_active IP Right Cessation
- 1976-12-01 NL NL7613376A patent/NL7613376A/xx unknown
- 1976-12-01 JP JP51143524A patent/JPS5915640B2/ja not_active Expired
- 1976-12-01 AT AT891076A patent/AT348687B/de not_active IP Right Cessation
- 1976-12-01 FR FR7636233A patent/FR2334109A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FI763446A (de) | 1977-06-02 |
| SE419871B (sv) | 1981-08-31 |
| CH625052A5 (de) | 1981-08-31 |
| SE7513495L (sv) | 1977-06-02 |
| AT348687B (de) | 1979-02-26 |
| NL7613376A (nl) | 1977-06-03 |
| AU2006176A (en) | 1978-06-08 |
| NO148960C (no) | 1984-01-18 |
| BE848932A (fr) | 1977-05-31 |
| JPS5297792A (en) | 1977-08-16 |
| DE2654189A1 (de) | 1977-06-08 |
| GB1562808A (en) | 1980-03-19 |
| DK537676A (da) | 1977-06-02 |
| NO148960B (no) | 1983-10-10 |
| ATA891076A (de) | 1978-07-15 |
| FI63494B (fi) | 1983-02-28 |
| DE2654189C3 (de) | 1985-10-03 |
| CA1060324A (en) | 1979-08-14 |
| JPS5915640B2 (ja) | 1984-04-10 |
| FR2334109B1 (de) | 1982-03-12 |
| US4139415A (en) | 1979-02-13 |
| NO764081L (de) | 1977-06-02 |
| FR2334109A1 (fr) | 1977-07-01 |
| DE2654189B2 (de) | 1979-03-08 |
| AU508343B2 (en) | 1980-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6756208B2 (en) | Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C | |
| FI63494C (fi) | Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod | |
| AU763466B2 (en) | A pharmaceutical preparation for treating blood coagulation disorders | |
| FI57421C (fi) | Foerfarande foer framstaellning av ett preparat ur maenniskoblodplasma med blodets koagulation befraemjande verkan | |
| Ofosu et al. | Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate | |
| CZ78693A3 (en) | Pharmaceutical preparation for treating prolongated coagulation period | |
| Thomsen et al. | Immunohistochemical detection of C5b-9 (m) in myocardium: an aid in distinguishing infarction-induced ischemic heart muscle necrosis from other forms of lethal myocardial injury | |
| FI64466B (fi) | Foerfarande och reagens foer bestaemning av protrombin | |
| Pabinger-Fasching et al. | High levels of plasma protein C in nephrotic syndrome | |
| Schoen et al. | Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments | |
| Cerletti et al. | Interaction between glycosaminoglycans, platelets, and leukocytes | |
| US7220553B2 (en) | Use of Russell's viper venom-induced plasma factor Xa activity to monitor the activity of factor Xa inhibitors | |
| Matsuda et al. | Selective determination of α2-plasmin inhibitor activity in plasma using chromogenic substrate | |
| US4882272A (en) | High molecular weight kininogen assay | |
| Sie et al. | Inactivation of heparin cofactor II by polymorphonuclear leukocytes | |
| Fischer et al. | Comparison between the effect of pentosan polysulphate heparin and antithrombin III injections in antithrombin III deficient patients | |
| Wages et al. | Structural characterization and functional effects of a circulating heparan sulfate in a patient with hepatocellular carcinoma | |
| Grau et al. | Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome | |
| Nigretto et al. | Contributions of negatively charged chemical groups to the surface-dependent activation of human plasma by soluble dextran derivatives | |
| Wagenvoord et al. | Development of a rapid and sensitive chromogenic heparin assay for clinical use | |
| CS226407B2 (en) | Method of determining mb creatinkinase | |
| Baruch et al. | Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III | |
| Hill et al. | Acquired heparin‐like anticoagulants: a second case in metastatic breast carcinoma and literature review | |
| Scully | The use of an automated analyzer in the evaluation of antithrombin III and heparin | |
| Nakhleh et al. | Heparin cofactor II assay: elimination of heparin and antithrombin-III effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: PHARMACIA AB |